Gutheil et al., 2000 - Google Patents
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin ανβ3Gutheil et al., 2000
- Document ID
- 3622608167246506342
- Author
- Gutheil J
- Campbell T
- Pierce P
- Watkins J
- Huse W
- Bodkin D
- Cheresh D
- Publication year
- Publication venue
- Clinical Cancer Research
External Links
Snippet
Angiogenesis plays a central role in the growth and metastasis of cancers. Strategies aimed at interfering with tumor blood supply offer promise for new cancer therapies. Vitaxin (an anti- ανβ3 antibody) interferes with blood vessel formation by inducing apoptosis in newly …
- 201000011510 cancer 0 title abstract description 38
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gutheil et al. | Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin ανβ3 | |
| DE69535405T2 (en) | ANGIOSTATIN AND METHOD FOR ITS USE TO AVOID THE ANGIOGENESIS | |
| Cobleigh et al. | A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer | |
| El-Assal et al. | The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma | |
| Bhargava et al. | A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer | |
| Wong et al. | Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis | |
| Hassouneh et al. | Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer | |
| Abrams et al. | Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer | |
| Ding et al. | Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas | |
| Bachelder et al. | Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells | |
| Sauter et al. | Cyclin D1 is a candidate oncogene in cutaneous melanoma | |
| Edwards et al. | Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK) | |
| Emmenegger et al. | A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens | |
| Estévez et al. | Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study | |
| Dings et al. | The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin | |
| Kaur et al. | Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism | |
| Tomita et al. | Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors | |
| Goi et al. | Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor | |
| DE69637179T2 (en) | ANGIOSTAT INFRAGMENTS AND METHOD FOR THEIR USE | |
| Rusk et al. | Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers | |
| Eikesdal et al. | Drug resistance associated with antiangiogenesis therapy | |
| Yokoyama et al. | Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model | |
| Dang et al. | Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments | |
| Komdeur et al. | Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target | |
| Bridgeman et al. | Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma |